Tobalina et al.7reported the occurrence of reversion mutations in 26.0% (86/327) patients with BRCA1 or BRCA2 mutations, including 27 patients with breast cancer, with a higher percentage in BRCA2 compared with BRCA1 (30.7% vs. 22.0%).7 This evidence concerns the gene BRCA2 and breast carcinoma.